Novo Nordisk Diagrams Response To FDA GMP Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The warning letter says Novo Nordisk’s initial response to findings of a March 2012 FDA inspection lack sufficient corrective action; the firm says it has responded to FDA’s concerns and that the letter should not impact any products marketed in the U.S.